66 results about "Virus vaccine" patented technology

The invention provides an influenza vaccine adjuvant based on lentinan as well as a preparation method and application thereof. The active ingredient of the vaccine adjuvant is lentinan, the lentinan is extracted from fresh lentinus edodes through a water extraction and alcohol precipitation method, no additional chemical modification is needed, the vaccine adjuvant can be used for preparing the influenza virus vaccine, and the influenza virus vaccine at least contains one of three inactivated influenza virus antigens, namely H1N1 A, H3N2 A and Victoria B. The invention also provides a vaccine preparation and a preparation method thereof, the vaccine preparation comprises the vaccine adjuvant and an influenza virus vaccine, the content of lentinan in the vaccine preparation is 4 mg / mL, and the vaccine preparation has an immunological enhancement effect.

The invention discloses an immunogenic composition containing an adjuvant as well as a preparation method and application of the immunogenic composition. The immunogenic composition comprises self-assembled gE virus-like nanoparticles, an immunopotentiator, namely, saponin QS-21, and a neutral liposome, the self-assembled gE virus-like nanoparticles are formed by polymerizing and assembling monomers; the monomers include VZV gE, a linker peptide (SGS), and a VZV gI polypeptide containing a Th epitope. The immunogenic composition can be applied to varicella-zoster virus vaccines, and solves the technical problems of weak gE immunogenicity and serious vaccine side reaction in vaccines prepared in the prior art. The immunogenicity of the vaccine is equivalent to that of the Xinanlii, and the use of an immunopotentiator in the vaccine can be reduced, so that the clinical side reaction of the vaccine is lower; in addition, the vaccine can induce a gI specific antibody and gI specific CMI reaction, and the effectiveness of the vaccine can be further improved. In short, the immunogenic composition has good clinical application potential.

The invention relates to a novel HSV-2 three-antigen recombinant protein vaccine composition and application thereof, and belongs to the technical field of biology. The vaccine composition comprises an antigen and a composite adjuvant, the antigen is HSV-2 gC2-gD2-gE2 three-antigen tandem recombinant protein, and the composite adjuvant is CpG oligonucleotide and an aluminum adjuvant; the amino acid sequence of the HSV-2 gC2-gD2-gE2 three-antigen tandem recombinant protein is as shown in SEQ ID NO. 1, and the nucleotide sequence of the HSV-2 gC2-gD2-gE2 three-antigen tandem recombinant protein is as shown in SEQ ID NO. 2. The time cost and the economic cost in the protein preparation process are greatly reduced, and compared with an original trivalent combination vaccine, the trivalent combination vaccine can induce the level of specific antibodies generated by mice and the virus neutralizing capacity not to be reduced, so that a brand new thought is provided for developing advanced HSV-2 virus vaccines with multiple target antigens, and the trivalent combination vaccine is worthy of popularization and application. Meanwhile, the invention also provides a safe and effective HSV-2 virus candidate vaccine.

The invention relates to a recombinant chimeric antigen aiming at bovine nodular skin disease virus, an immunogenic composition containing the recombinant chimeric antigen and application of the recombinant chimeric antigen. The bovine nodular skin disease virus recombinant chimeric antigen comprises two immunogens which are connected in series and fused according to a specific sequence: bovine nodular skin disease virus ORF122 and ORF060 proteins or antigenic fragments thereof, and can excite immune response aiming at two infectious virus particles, namely, intracellular mature virus particles (IMV) and cell outer enveloped virus particles (EEV); therefore, the specific immune protection effect on the bovine nodular skin disease virus is efficiently excited; in addition, the bovine nodular skin disease virus vaccine disclosed by the invention also has good safety, quick responsiveness and productivity support, and has an extremely good clinical application prospect.

The invention relates to a primer-probe set, comprising a forward primer having the nucleotide sequence of SEQ ID NO:1 and a reverse primer having the nucleotide sequence of SEQ ID NO:2, and a peptide nucleic acid (PNA) probe having the sequence of HEX-OO-(SEQ ID NO:3)-Lysine-BHQ1, which are used for differentiating the Peste des Petits Ruminants (PPR) virus vaccine and field strains and for preventing false positive results arising from the PPR vaccine, as well as to their operating temperatures. Said primer-probe set can differentiate between the vaccine strain containing the nucleotide sequence of SEQ ID NO:4 and the field strain containing the nucleotide sequence of SEQ ID NO:5. Thus, by means of said primer-probe set, false positive results arising from the PPR vaccine are prevented, and accordingly, unnecessary quarantine measures are also avoided.

Provided herein are compositions, systems, kits, and methods for immunizing a subject against severe fever with thrombocytopenia syndrome virus (SFTS virus) using a composition comprising: i) a plurality of nanoparticles self-assembled from a plurality of fusion proteins comprising a) at least a portion of a ferritin protein, and b) at least a portion of an immunogenic protein comprising at least a portion of the SFTS virus Gn and / or Gc envelope glycoprotein; or ii) a polynucleotide encoding the fusion protein (e.g., an mRNA sequence present in a lipid nanoparticle).

The present disclosure provides a vaccine composition that comprises an Epstein Barr Virus (EBV) polypeptide and a liposomal adjuvant, and methods of inducing an immune response to an Epstein Barr Virus (EBV) or methods of preventing infection of or reducing the likelihood of infection by an Epstein Barr Virus (EBV) using the compositions, or a combination of the EBV polypeptide and the liposomal adjuvant.

The application provides a varicella-zoster virus vaccine and application thereof, and belongs to the technical field of vaccines.The varicella-zoster virus vaccine comprises liposome nanoparticles, zoster virus glycoprotein E and an adjuvant encapsulated in the liposome nanoparticles.The adjuvant comprises triterpenoid saponins.In the application, the zoster virus glycoprotein E (gE) is wrapped by the liposome nanoparticles, which can effectively promote antigen-presenting cells to phagocytose and efficiently deliver the antigen, and realize sustained stimulation of the vaccine to the body to produce a specific cellular immune response against VZV-gE.The triterpenoid saponins used in the application can effectively realize cross-presentation of the antigen zoster virus glycoprotein E and induce an antigen-specific cellular immune response.In addition, the cholesterol rich in the liposome nanoparticles can effectively neutralize the cytotoxicity of the triterpenoid saponins, ensuring the safety of the vaccine.

The invention discloses a pelteobagrus fulvidraco brain tissue cell line PYCB sensitive to viruses and application thereof, and belongs to the technical field of aquatic organism cell culture and disease prevention and control. The preservation number of the Pelteobagrus fulvidraco brain tissue cell line PYCB is CCTCC (China Center For Type Culture Collection) NO: C2025148. The Pelteobagrus fulvidraco brain tissue cell line PYCB is successfully constructed by taking the Pelteobagrus fulvidraco brain tissue as an object, and the cell line can be continuously and stably subcultured, is high in proliferation speed and simple in culture method, is sensitive to Pelteobagrus fulvidraco small RNA viruses and Pelteobagrus fulvidraco stem casing viruses, and can be used for isolated culture of viruses. The invention provides an important research platform and an experimental material for separating and identifying fish viruses and virus vaccines and developing medicines.

The present application relates to an avian cell line capable of supporting viral growth of Marek's Disease Virus (MDV), including Herpes Virus of Turkeys (HVT), methods of producing such cell lines, and therapeutic uses of the cell lines and resulting vaccines.

The application provides a KRT31 gene knockout cell line and its application in promoting replication of viruses of the Picornaviridae family and / or production of vaccines of viruses of the Picornaviridae family, and belongs to the technical field of genetic engineering. The application provides an application of a KRT31 gene or a coded protein thereof as a target in preparation of a product for regulating replication of viruses of the Picornaviridae family and / or vaccine production. Up-regulation of the expression level of the KRT31 gene can inhibit replication of viruses of the Picornaviridae family, and down-regulation of the expression level of the KRT31 gene can promote replication of viruses of the Picornaviridae family. The application adopts sgRNA to knockout the KRT31 gene to prepare a cell line with lost function of a gene coded protein, so as to promote replication of viruses of the Picornaviridae family, improve virus titer and antigen yield, and help to efficiently prepare vaccines of viruses of the Picornaviridae family.

The present invention relates to polynucleotides comprising a sequence of a live, infectious, attenuated Flavivirus wherein a nucleotide sequence encoding at least a part of a Filovirus glycoprotein is located at the intergenic region between the E and NS1 gene of said Flavivirus, such that a chimeric virus is expressed, characterised in that the encoded sequence C terminally of the E protein of said Flavivirus and N terminally of the signal peptide of the NS1 protein of said Flavivirus comprises in the following order: a further signal peptide of a Flavivirus NS1 protein, a filovirus glycoprotein wherein the N terminal signal peptide is absent, a TM domain of a flaviviral E protein.

The invention relates to a recombinant chikungunya virus vaccine as well as a preparation method and application thereof, in particular to a recombinant protein which comprises chikungunya virus protein or a variant thereof. The chikungunya fever virus serving as a main target of a neutralizing antibody is optimized, new nanoparticle protein is formed and used for preparing the vaccine, and the vaccine can stimulate an organism to generate the neutralizing antibody aiming at the chikungunya fever virus and prevent in-vivo infection and has a good neutralizing effect.

The invention belongs to the field of gene engineering, and particularly relates to establishment of an ALKBH5 gene knockout cell line and application of the ALKBH5 gene knockout cell line as a foot-and-mouth disease virus vaccine production cell line. According to the invention, firstly, the ALKBH5 gene knockout BHK-21 cell line is successfully constructed by using a CRISPR / Cas9 technology, after ALKBH5 is knocked out, the cell activity is not obviously influenced, but the replication of FMDV can be obviously promoted, and the ALKBH5 gene knockout BHK-21 cell line can be used as a production cell line of a foot and mouth disease virus vaccine; and secondly, by constructing an ALKBH5 wild type and an R131 site mutation plasmid and carrying out a back-up experiment, the result shows that the ALKBH5 can inhibit the replication of the FMDV. The invention discloses the negative regulation effect of ALKBH5 as a host factor on FMDV replication for the first time, and lays an important theoretical foundation for deep analysis of a molecular mechanism of ALKBH5.

The invention belongs to the field of gene engineering, and particularly relates to construction of an RNF31 gene knockout cell line and application of the RNF31 gene knockout cell line as a foot-and-mouth disease virus vaccine production cell line. The method comprises the following steps: firstly, designing two sgRNA sequences at an RNF31 exon by utilizing a CRISPR / Cas9 technology, and connecting with a pX459-puro vector to construct a recombinant plasmid; the method comprises the following steps: transfecting a PK-15 cell with pX459-RNF31-sgRNA, and screening under the action of puromycin, so as to obtain the RNF31 gene knockout cell line. Compared with a wild type cell, the RNF31 gene knockout cell line remarkably promotes FMDV replication and can be used as a production cell line of a foot and mouth disease virus vaccine; and data support is provided for further researching a mechanism of inhibiting FMDV replication by RNF31.

The present invention provides new canine Influenza H3N2 vaccines, including multivalent vaccines. The present invention provides an alphavirus RNA replicon particle that encodes a Canine Influenza (CIV) H3N2 hemagglutinin (HA) antigen. The present invention further provides methods of making and using the vaccines.

The invention relates to a recombinant chimeric antigen aiming at bovine nodular skin disease virus as well as a preparation method and application of the recombinant chimeric antigen. The bovine nodular skin disease virus recombinant chimeric antigen comprises four immunogens which are connected in series and fused according to a specific sequence: bovine nodular skin disease virus ORF122, ORF060, ORF074 and ORF117 proteins or antigenic fragments thereof, and can excite immune response aiming at two infectious virus particles, namely, intracellular mature virus particles (IMV) and extracellular membrane virus particles (EEV); therefore, the specific immune protection effect on the bovine nodular skin disease virus is efficiently excited; in addition, the bovine nodular skin disease virus vaccine disclosed by the invention also has good safety, quick responsiveness and productivity support, and has an extremely good clinical application prospect.

The present application belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition, a preparation method and application thereof. Specifically, based on the theory of traditional Chinese veterinary medicine of'strengthening the body resistance and eliminating pathogenic factors, and treating the root and branch', aiming at the pathogenesis of 'deficiency in the root and excess in the branch' of low immunity in animals, eight kinds of medicinal materials are scientifically screened to form a traditional Chinese medicine compound with the effects of tonifying qi and nourishing blood, invigorating the spleen and kidney, dredging collaterals and eliminating dampness, and clearing heat and detoxifying. Through the verification of a cyclophosphamide-induced low immunity mouse model, the traditional Chinese medicine composition can significantly improve the mental state of the mice, restore the body weight and thymus / spleen index, repair the pathological damage of the spleen tissue, and adjust the inflammatory factor level in the serum and spleen tissue. In addition, in a Marek's disease virus infection model, the traditional Chinese medicine composition combined with the Marek's disease virus vaccine can significantly reduce the viral load in the peripheral blood, liver and spleen, and reduce the liver enlargement, hemorrhage and microscopic structure damage, showing a good immune synergistic effect.

Provided herein are (i) messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding a soluble Nipah virus glycoprotein (soluble NiV-G) fused to a human type I collagen alpha 1 (COL1A1) signal peptide, (ii) an mRNA comprising an ORF encoding the full-length Nipah virus glycoprotein (full-length NiV-G), (iii) an mRNA comprising an ORF encoding the full-length Nipah virus fusion protein (full-length NiV-F), or (iv) an mRNA comprising an ORF encoding full-length NiV-G and an ORF encoding full-length NiV-F, as well as methods for inducing an immune response against Nipah virus by administering an effective amount of the Nipah virus vaccine composition to a subject in need thereof.

The application belongs to the technical field of genetic engineering, and particularly relates to a fusion protein HN-RBD, a coding gene, a recombinant NDV virus carrier, a recombinant NDV virus and application thereof; the fusion protein HN-RBD comprises a partial domain of a Newcastle disease virus HN protein and a RBD of a S protein of a new coronavirus; the partial domain of the Newcastle disease virus HN protein comprises an intracellular domain and a transmembrane domain of the Newcastle disease virus HN protein. When a coding sequence of the fusion protein HN-RBD is combined with a coding sequence of the S protein of the new coronavirus or a variant of the S protein of the new coronavirus and is jointly inserted into the NDV virus carrier, more S proteins of the new coronavirus can be displayed on the surface of a recombinant NDV virus particle, and the ability of the recombinant NDV virus to produce mucosal immune antibody IgA is improved, which has great significance for developing an excellent recombinant NDV virus vaccine candidate strain.

The application discloses a Gitta virus genetically engineered subunit vaccine and a preparation method and application thereof, and belongs to the technical field of vaccine preparation. The Gitta virus P6E recombinant protein is obtained by using a eukaryotic expression system, and is further loaded on the surface of a nanoparticle skeleton to form a recombinant nanoparticle. The obtained recombinant protein and the recombinant nanoparticle are respectively compounded with an adjuvant to prepare the genetically engineered subunit vaccine. After twice immunization, the vaccines of the two components can significantly induce the host to produce strong humoral immune and cellular immune responses, thereby providing effective protection against GETV infection. The technical scheme of the application provides an important technical basis and application reference for research and optimization of the Gitta virus vaccine.

The invention relates to a monkey pox virus vaccine based on a chimpanzee adenovirus vector, the chimpanzee adenovirus vector expresses a monkey pox virus immunizing antigen, and the monkey pox virus immunizing antigen comprises one or more of A35R, M1R and A29L. The monkey pox virus vaccine provided by the invention has the advantages of good immune effect, strong stability and the like.

Disclosed herein are respiratory syncytial virus vaccines and methods of immunization for delivering respiratory syncytial virus vaccines in a subject.

The invention relates to a respiratory syncytial virus vaccine composition and application thereof. The recombinant respiratory syncytial virus vaccine comprises RSVpreF protein and a pharmaceutically acceptable composite adjuvant carrier, and the composite adjuvant carrier is formed by combining an aluminum adjuvant with a CpG adjuvant. Experimental results prove that the vaccine composition provided by the invention has good immunogenicity and a better immune effect.

The present specification provides: a Newcastle disease virus with improved heat resistance; a Newcastle disease vaccine comprising the virus; a polypeptide comprising an L protein in the virus; a polynucleotide encoding same; and a recombinant vector comprising the polynucleotide.

The invention relates to a recombinant CHO cell strain capable of efficiently inducing and expressing swine foot-and-mouth disease VLP as well as a preparation method and application of the recombinant CHO cell strain. The method comprises the following steps: firstly, screening a monoclonal cell strain capable of stably inducing expression of FMDV 3C protease by taking CHO-B40 (GS defective strain) as a host cell and taking hygromycin and GS as screening markers in a CHO cell strain stable transformation mode, naming the monoclonal cell strain as CHO-FMDV-3C-3D6 cell strain, and then, carrying out recombinant expression of FMDV 3C protease by taking the CHO-FMDV-3C-3D6 cell strain as a host cell. The CHO-FMDV-3C-VLP-4D8 cell strain capable of stably expressing the P12A protein of the foot and mouth disease virus is screened through MSX, the cell strain can only induce expression of 3C protease under the action of an inducer GLP-1 in the culture process, the expressed 3C protease cuts the expressed P12A protein of the FMDV, the cut protein is self-assembled to form FMDV VLP, and the FMDV VLP is separated from the FMDV VLP. The purified VLP and an ISA201 adjuvant are emulsified to prepare an FMDV vaccine, and the FMDV vaccine has good immunogenicity and is beneficial to the development of the swine foot-and-mouth disease virus vaccine industry.

The present invention relates to formulations of dengue virus vaccine comprising at least one live attenuated dengue virus or live attenuated chimeric flavivirus, a buffer, a sugar, a cellulose derivative, a glycol or sugar alcohol, optionally an alkali or alkaline salt and an amino acid; and formulations of dengue virus vaccine comprising at least one live attenuated dengue virus or live attenuated chimeric flavivirus, a buffer, a sugar of at least 150 mg / ml, a carrier, and optionally an alkali or alkaline salt and an amino acid.

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to non-self-replicating RNA betacoronavirus vaccines formulated in a lipid nanoparticle.

The invention relates to the technical field of biomedicine, and specifically to a method for treating tumors using a combination of an oncolytic virus vaccine and immune cells. The method specifically comprises the following steps: treating a tumor by using a combination of immune cells and an oncolytic virus vaccine; the oncolytic virus vaccine comprising a recombinant oncolytic virus expressing a tumor antigen, and used for targeting tumor cells; the immune cells are embedded in an antigen receptor paired with the tumor antigen, and are used for killing or destroying tumor cells of a target; and the recombinant oncolytic virus comprises an M protein, G protein, N protein, P protein, and L protein, following site-directed mutagenesis. The combination of the oncolytic virus vaccine and the immune cells for killing or destroying the tumor antigen is used for attacking and killing tumor cells, and the tumor antigen expressed by the oncolytic virus vaccine can not only guide the immune cells to reach the center of a target tumor tissue, but the combination of the oncolytic virus and immune cells to kill tumor cells achieves a curative effect where 1+1 is greater than 2, with a maximum tumor cell killing rate being able to reach 100%.

The invention belongs to the technical field of bioengineering, and particularly relates to a banana streak virus vaccine and application thereof in prevention and treatment of banana streak virus diseases. Through research and exploration, the banana streak virus vaccine constructed based on an endogenous banana streak virus sequence carried by a banana genome is developed, and after the banana streak virus vaccine is applied to banana plants, the replication of the banana streak virus can be remarkably inhibited, and the infection of the banana streak virus and the development of the banana streak virus can be controlled. The invention provides a new strategy for simply, conveniently and effectively preventing and treating banana streak virus diseases, and is particularly suitable for large-scale banana planting areas.